Buurman, D J <br/><br/>
Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.  [electronic resource] 

 -  PloS one  2018 
 - e0208922 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1932-6203 
<br/><br/><label>Standard No.: </label>10.1371/journal.pone.0208922  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab--administration & dosage<br/>Adult<br/>Aged<br/>Antibodies, Anti-Idiotypic--blood<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Neutralizing<br/>Biological Products--administration & dosage<br/>Biosimilar Pharmaceuticals--administration & dosage<br/>Certolizumab Pegol--administration & dosage<br/>Cross Reactions--immunology<br/>Etanercept--administration & dosage<br/>Female<br/>Humans<br/>Inflammatory Bowel Diseases--blood<br/>Infliximab--administration & dosage<br/>Male<br/>Middle Aged<br/>Tumor Necrosis Factor-alpha--blood